Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined … Read more
Jinyu Bio-Technology Co Ltd (600201) - Net Assets
Latest net assets as of September 2025: CN¥5.65 Billion CNY
Based on the latest financial reports, Jinyu Bio-Technology Co Ltd (600201) has net assets worth CN¥5.65 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.73 Billion) and total liabilities (CN¥1.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.65 Billion |
| % of Total Assets | 83.94% |
| Annual Growth Rate | 15.7% |
| 5-Year Change | 2.9% |
| 10-Year Change | 161.79% |
| Growth Volatility | 55.48 |
Jinyu Bio-Technology Co Ltd - Net Assets Trend (1995–2024)
This chart illustrates how Jinyu Bio-Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jinyu Bio-Technology Co Ltd (1995–2024)
The table below shows the annual net assets of Jinyu Bio-Technology Co Ltd from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.42 Billion | -4.24% |
| 2023-12-31 | CN¥5.65 Billion | +5.71% |
| 2022-12-31 | CN¥5.35 Billion | -3.79% |
| 2021-12-31 | CN¥5.56 Billion | +5.65% |
| 2020-12-31 | CN¥5.26 Billion | +8.09% |
| 2019-12-31 | CN¥4.87 Billion | -6.77% |
| 2018-12-31 | CN¥5.22 Billion | +16.63% |
| 2017-12-31 | CN¥4.48 Billion | +19.33% |
| 2016-12-31 | CN¥3.75 Billion | +81.41% |
| 2015-12-31 | CN¥2.07 Billion | +26.87% |
| 2014-12-31 | CN¥1.63 Billion | +27.20% |
| 2013-12-31 | CN¥1.28 Billion | +18.95% |
| 2012-12-31 | CN¥1.08 Billion | +8.73% |
| 2011-12-31 | CN¥991.13 Million | +17.41% |
| 2010-12-31 | CN¥844.15 Million | +12.41% |
| 2009-12-31 | CN¥750.98 Million | +3.80% |
| 2008-12-31 | CN¥723.47 Million | +2.11% |
| 2007-12-31 | CN¥708.54 Million | +16.96% |
| 2006-12-31 | CN¥605.80 Million | +4.96% |
| 2005-12-31 | CN¥577.16 Million | -5.23% |
| 2004-12-31 | CN¥609.02 Million | +6.11% |
| 2003-12-31 | CN¥573.94 Million | +8.33% |
| 2002-12-31 | CN¥529.82 Million | +2.44% |
| 2001-12-31 | CN¥517.19 Million | +50.00% |
| 2000-12-31 | CN¥344.80 Million | +3.05% |
| 1999-12-31 | CN¥334.58 Million | +0.46% |
| 1998-12-31 | CN¥333.06 Million | +300.33% |
| 1997-12-31 | CN¥83.20 Million | +4.74% |
| 1996-12-31 | CN¥79.43 Million | +0.74% |
| 1995-12-31 | CN¥78.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jinyu Bio-Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 107256.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.15 Billion | 59.19% |
| Common Stock | CN¥1.12 Billion | 21.08% |
| Other Components | CN¥1.05 Billion | 19.73% |
| Total Equity | CN¥5.31 Billion | 100.00% |
Jinyu Bio-Technology Co Ltd Competitors by Market Cap
The table below lists competitors of Jinyu Bio-Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eagers Automotive Ltd
AU:APE
|
$1.90 Billion |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
$1.90 Billion |
|
Paycor HCM Inc
NASDAQ:PYCR
|
$1.90 Billion |
|
Beta Technologies, Inc.
NYSE:BETA
|
$1.90 Billion |
|
HELLA GmbH & Co. KGaA
PINK:HLKHF
|
$1.90 Billion |
|
Alleima AB (publ)
OTCGREY:SAMHF
|
$1.90 Billion |
|
Emmi AG
PINK:EMLZF
|
$1.90 Billion |
|
Nihon Unisys Ltd
MU:NIU
|
$1.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jinyu Bio-Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,366,883,193 to 5,314,336,328, a change of -52,546,865 (-1.0%).
- Net income of 108,985,190 contributed positively to equity growth.
- Dividend payments of 89,365,410 reduced retained earnings.
- Other factors decreased equity by 72,166,645.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥108.99 Million | +2.05% |
| Dividends Paid | CN¥89.37 Million | -1.68% |
| Other Changes | CN¥-72.17 Million | -1.36% |
| Total Change | CN¥- | -0.98% |
Book Value vs Market Value Analysis
This analysis compares Jinyu Bio-Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 166.71x to 3.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.09 | CN¥15.10 | x |
| 1996-12-31 | CN¥0.09 | CN¥15.10 | x |
| 1997-12-31 | CN¥0.10 | CN¥15.10 | x |
| 1998-12-31 | CN¥0.38 | CN¥15.10 | x |
| 1999-12-31 | CN¥0.38 | CN¥15.10 | x |
| 2000-12-31 | CN¥0.39 | CN¥15.10 | x |
| 2001-12-31 | CN¥0.59 | CN¥15.10 | x |
| 2002-12-31 | CN¥0.60 | CN¥15.10 | x |
| 2003-12-31 | CN¥0.65 | CN¥15.10 | x |
| 2004-12-31 | CN¥0.70 | CN¥15.10 | x |
| 2005-12-31 | CN¥0.66 | CN¥15.10 | x |
| 2006-12-31 | CN¥0.61 | CN¥15.10 | x |
| 2007-12-31 | CN¥0.68 | CN¥15.10 | x |
| 2008-12-31 | CN¥0.71 | CN¥15.10 | x |
| 2009-12-31 | CN¥0.74 | CN¥15.10 | x |
| 2010-12-31 | CN¥0.82 | CN¥15.10 | x |
| 2011-12-31 | CN¥0.96 | CN¥15.10 | x |
| 2012-12-31 | CN¥1.04 | CN¥15.10 | x |
| 2013-12-31 | CN¥1.25 | CN¥15.10 | x |
| 2014-12-31 | CN¥1.60 | CN¥15.10 | x |
| 2015-12-31 | CN¥2.01 | CN¥15.10 | x |
| 2016-12-31 | CN¥3.54 | CN¥15.10 | x |
| 2017-12-31 | CN¥3.90 | CN¥15.10 | x |
| 2018-12-31 | CN¥4.40 | CN¥15.10 | x |
| 2019-12-31 | CN¥4.20 | CN¥15.10 | x |
| 2020-12-31 | CN¥4.45 | CN¥15.10 | x |
| 2021-12-31 | CN¥4.69 | CN¥15.10 | x |
| 2022-12-31 | CN¥4.66 | CN¥15.10 | x |
| 2023-12-31 | CN¥4.94 | CN¥15.10 | x |
| 2024-12-31 | CN¥4.83 | CN¥15.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jinyu Bio-Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.68%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.27x
- Recent ROE (2.05%) is below the historical average (12.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 24.89% | 20.34% | 0.45x | 2.70x | CN¥11.74 Million |
| 1996 | 27.28% | 22.19% | 0.47x | 2.64x | CN¥13.72 Million |
| 1997 | 29.86% | 16.42% | 0.74x | 2.45x | CN¥16.53 Million |
| 1998 | 6.46% | 13.86% | 0.35x | 1.32x | CN¥-11.80 Million |
| 1999 | 8.87% | 17.80% | 0.35x | 1.43x | CN¥-3.77 Million |
| 2000 | 5.19% | 9.07% | 0.34x | 1.66x | CN¥-16.52 Million |
| 2001 | 2.76% | 6.83% | 0.27x | 1.48x | CN¥-37.37 Million |
| 2002 | 7.68% | 13.70% | 0.36x | 1.55x | CN¥-12.16 Million |
| 2003 | 7.78% | 13.22% | 0.35x | 1.69x | CN¥-12.58 Million |
| 2004 | 7.29% | 9.47% | 0.44x | 1.74x | CN¥-16.46 Million |
| 2005 | 2.14% | 2.22% | 0.53x | 1.82x | CN¥-45.23 Million |
| 2006 | 6.33% | 6.81% | 0.60x | 1.56x | CN¥-22.16 Million |
| 2007 | 13.32% | 13.23% | 0.54x | 1.86x | CN¥23.14 Million |
| 2008 | 10.11% | 8.86% | 0.66x | 1.74x | CN¥820.76K |
| 2009 | 8.85% | 9.84% | 0.48x | 1.86x | CN¥-8.62 Million |
| 2010 | 13.74% | 17.18% | 0.42x | 1.90x | CN¥31.38 Million |
| 2011 | 15.13% | 25.94% | 0.33x | 1.75x | CN¥50.69 Million |
| 2012 | 12.12% | 23.44% | 0.30x | 1.75x | CN¥22.85 Million |
| 2013 | 19.57% | 37.37% | 0.39x | 1.34x | CN¥122.70 Million |
| 2014 | 24.76% | 38.04% | 0.51x | 1.29x | CN¥241.06 Million |
| 2015 | 23.19% | 38.49% | 0.49x | 1.23x | CN¥272.85 Million |
| 2016 | 17.19% | 42.49% | 0.35x | 1.16x | CN¥269.60 Million |
| 2017 | 19.46% | 45.77% | 0.33x | 1.27x | CN¥423.03 Million |
| 2018 | 15.00% | 39.78% | 0.30x | 1.25x | CN¥251.32 Million |
| 2019 | 4.76% | 19.62% | 0.20x | 1.20x | CN¥-243.69 Million |
| 2020 | 8.15% | 25.68% | 0.25x | 1.26x | CN¥-91.97 Million |
| 2021 | 7.25% | 21.52% | 0.27x | 1.25x | CN¥-144.94 Million |
| 2022 | 4.15% | 13.78% | 0.24x | 1.26x | CN¥-296.56 Million |
| 2023 | 5.28% | 17.75% | 0.23x | 1.28x | CN¥-253.06 Million |
| 2024 | 2.05% | 8.68% | 0.19x | 1.27x | CN¥-422.45 Million |
Industry Comparison
This section compares Jinyu Bio-Technology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jinyu Bio-Technology Co Ltd (600201) | CN¥5.65 Billion | 24.89% | 0.19x | $1.90 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |